Obermatt
See Similar Stocks →

Flags

Financial distress

Travere Therapeutics

NMQ:TVTX · US89422G1076
BiotechnologyMedium

360

53
Profit price19
Cash yield1
Price/Sales70
EV / Gross Profit41
Price/Book13
Return on Capital66
Return on Equity18
EBIT Margin40
Gross Profitability91

Cash truth not applicable for financial companies.

Sales growth59
Profit growth91
Reinvestment33
Price momentum96
Debt load13
Debt serviceability75
Liquidity67
Analyst ratings45
Opinion Changes50
Price Target Upside19
Market mood43
Value Creation17/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Travere Therapeutics generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Websitetravere.com
ISINUS89422G1076
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
UrologyNephrologyGeneticsGenetic DisorderBiotechnologyHealth CareMedical

Description

Travere Therapeutics, Inc. operates as a biopharmaceutical company. The company focuses on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. In September 2024, the U.S. Food and…

Analysis

Middle-of-the-road

Travere Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 17/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
40
2026

All-time high

40

Jun 2026

All-time low

13

Mar 2026

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
70
—
—
—
Price/Earnings
3
—
—
—
Price/Book
13
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
1
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Travere Therapeutics with its peers
Spero Therapeutics
NSQ:SPRO
77
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Biogen Idec
NSQ:BIIB
82
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Axsome Therapeutics
NMQ:AXSM
43
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Forte Biosciences
NAQ:FBRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →